Regeneron entered a multi-target Helicon partnership with Parabilis Medicines, taking an initial stake and committing $125 million up front with up to about $2.2 billion in additional milestones plus royalties for the platform effort. The collaboration is aimed at developing antibody-drug-conjugate-like therapeutics designed for hard-to-reach targets. The deal underscores Regeneron’s need to replenish its oncology portfolio after setbacks in late-stage immune checkpoint development. Under the agreement, Regeneron will leverage Parabilis’ Helicon peptide platform across five undisclosed targets. Markets will be tracking whether Regeneron’s Helicon strategy can translate platform differentiation into clinical differentiation, particularly as investors push for clear mechanistic and manufacturing feasibility advantages in next-generation ADC-like modalities.